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Abstract
Background: Histological chorioamnionitis (HC) is an intrauterine inflammatory process highly associated with preterm
birth and adverse neonatal outcome. HC is often clinically silent and diagnosed postnatally by placental histology. Earlier
identification could facilitate treatment individualisation to improve outcome in preterm newborns.
Aim: Develop a clinical prediction rule at birth for HC and HC with fetal involvement (HCF) in preterm newborns.
Methods: Clinical data and placental pathology were obtained from singleton preterm newborns (gestational age #32.0
weeks) born at Erasmus UMC Rotterdam from 2001 to 2003 (derivation cohort; n = 216) or Ma´xima MC Veldhoven from 2009
to 2010 (validation cohort; n = 206). HC and HCF prediction rules were developed with preference for high sensitivity using
clinical variables available at birth.
Results: HC and HCF were present in 39% and 24% in the derivation cohort and in 44% and 22% in the validation cohort,
respectively. HC was predicted with 87% accuracy, yielding an area under ROC curve of 0.95 (95%CI = 0.92–0.98), a positive
predictive value of 80% (95%CI = 74–84%), and a negative predictive value of 93% (95%CI = 88–96%). Corresponding figures
for HCF were: accuracy 83%, area under ROC curve 0.92 (95%CI = 0.88–0.96), positive predictive value 59% (95%CI = 52–
62%), and negative predictive value 97% (95%CI = 93–99%). External validation expectedly resulted in some loss of test
performance, preferentially affecting positive predictive rather than negative predictive values.
Conclusion: Using a clinical prediction rule composed of clinical variables available at birth, HC and HCF could be predicted
with good test characteristics in preterm newborns. Further studies should evaluate the clinical value of these rules to guide
early treatment individualisation.
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Introduction
Chorioamnionitis is an antenatal inflammatory state of the
intrauterine environment strongly associated with prematurity [1].
Around 40% of infants born before 32 weeks gestation have been
exposed to chorioamnionitis [1–3], which often is a clinically silent
process. Exposure to chorioamnionitis is known to affect several
organ systems in the fetus [4]. Its presence in placentas from
preterm infants has been associated with decreased respiratory
distress syndrome, but increased incidences of bronchopulmonary
dysplasia (BPD), necrotising enterocolitis (NEC) and neurologic
sequelae, including white matter damage and cerebral palsy [2,4–
6]. These effects have generally been shown to be more
pronounced when additional signs of fetal inflammation including
funisitis are present [2,4,5].
Recent studies have suggested differential effects of distinct
treatments in infants with varying degrees of chorioamnionitis as
opposed to non-exposed infants in the early neonatal period [7–
10]. Thus, perinatal identification of chorioamnionitis-exposed
infants could facilitate the development of subgroup-targeted early
intervention strategies to improve outcome in this group. Evidence
from randomised controlled trials and observational studies
suggests that chorioamnionitis-exposed infants may distinctively
benefit from increased surfactant dosing [8,10], restrictive use of
invasive and prolonged ventilation [8,11–13], as well as postnatal
corticosteroid administration to improve BPD-free survival [9].
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The gold standard for diagnosing chorioamnionitis is placental
histological examination [14]. Unfortunately in current practice,
the final results of placental pathology may take days if not weeks,
hindering its use as an indicator to guide early postnatal therapy.
To overcome this problem, the ability of biological markers to
detect chorioamnionitis before or shortly after birth has been
investigated. Indeed, several markers and marker patterns in
amniotic fluid and umbilical cord blood have been shown to carry
predictive value for histological chorioamnionitis [15–17]. How-
ever, to date their use is experimental, and sensitivity and
specificity have generally shown to be at best moderate.
Several clinical variables are well known to be distributed in a
differential pattern among preterm infants with and without
chorioamnionitis [2,5,18]. In the current study we aimed to
develop a clinical prediction rule for both histological chorioam-
nionitis (HC) and chorioamnionitis with fetal involvement (HCF)
at birth in preterm infants, composed solely of clinical variables
available at that time.
Methods
Ethics statement
The derivation cohort was part of a study approved by the
Medical Ethics Committee for Research on Human Subjects of
the Erasmus University MC. Written parental consent was
obtained. According to Dutch law a waiver for ethical assessment
and parental consent was provided by the local Medical Ethical
Committee of the Ma´xima Medical Centre for development and
use of the validation cohort, considering that retrospective and
anonymised data collection was performed using routinely
collected medical chart data solely.
Derivation cohort
The clinical prediction rule was developed in a prospective
cohort described previously [2,8,19]. Pregnant women, who
delivered between May 2001 and February 2003 in the Erasmus
University MC–Sophia Children’s Hospital in Rotterdam, Nether-
lands, at a gestational age of 32.0 weeks or less, were eligible for
the study. Newborns were enrolled immediately after delivery
when admitted to the neonatal intensive care unit (NICU; level
III). Trained research nurses unaware of results of placental
histology prospectively collected relevant clinical data. Multiple
births were excluded from analysis, as were newborns with severe
congenital abnormalities.
Placentas and membranes were fixed in formalin directly after
delivery. Sampling was done according to a standard protocol and
included at least two membrane rolls, two cross-sections of the
cord, and three representative blocks of the placental disk. Tissues
were embedded in paraffin until examination. A single pathologist
(RRdK) examined all placentas in a blinded fashion for presence
of chorioamnionitis and additional fetal inflammatory response,
according to the Amniotic Fluid Infection Nosology Committee
guidelines [14]. Accordingly, fetal involvement included any of the
following: chorionic vasculitis, umbilical phlebitis or vasculitis,
(subacute) necrotising funisitis, or concentric umbilical perivascu-
litis.
Predictors
Clinical variables were considered as potential predictors when
they were deemed to be readily available in daily practice, were
available in the prospectively collected database of the derivation
cohort, and were potentially associated with HC and/or HCF –
either positively or negatively – or had been associated with these
entities in prior clinical studies. According to these criteria, the
following clinical parameters were evaluated as potential predic-
tors of HC and HCF: ethnicity (self-classified); maternal age;
gravidity; parity; antenatal steroid administration (betamethasone
12 mg intramuscularly, repeated after 24 hours); preeclampsia
(new onset hypertension [blood pressure .140/90 mm Hg or
mean arterial pressure .105 mm Hg] with proteinuria); HELLP
syndrome (clinical presentation of intravascular haemolysis,
elevated liver enzymes, and a low platelet count); preterm
premature rupture of membranes (PPROM); clinical chorioamni-
onitis (maternal temperature .38.0uC with no other focus, and
two or more of the following: uterine tenderness, malodorous
vaginal discharge, maternal leukocytosis [WBC.15,000 cells/mL],
raised serum C-reactive protein [CRP.15 mg/L], maternal
tachycardia [.100 bpm], and fetal tachycardia [.160 bpm]);
mode of delivery; gestational age (preferably estimated by
ultrasonography or otherwise by using the last menstrual period
when reliable); gender; birth weight; being small for gestational
age (SGA; birth weight ,10th percentile of the gender-specific
mean for gestational age); and placental weight.
Clinical prediction rule development
Clinical prediction rule development methodology was guided
by published standards [20]. Univariable analyses were performed
to identify relevant clinical variables that differed between the
groups (‘no HC’ versus ‘HC’, and ‘no HCF’ versus ‘HCF’), using
x2-test, Student t test, or Mann-Whitney U-test where appropriate
(alpha ,0.10). These were entered into a backward logistic
regression model to predict either HC or HCF. Before entry,
continuous variables were dichotomised based on the most
discriminative cut-off value on the ROC curve. The final model
was selected using the likelihood ratio method with an alpha level
of 0.10. Next, for each predictor in the model the beta value was
divided by the lowest beta value in the model and rounded off to
the nearest integer. A weighted score was thus obtained for each
predictor and used to develop a clinical prediction rule for HC or
HCF. ROC curves were computed based on individual composite
scores calculated for each patient to determine the optimum cut-
off value for prediction, defined as the cut-off with a sensitivity of
at least 0.80 and maximum specificity. Relevant test statistics were
computed from two-by-two contingency tables. Internal model
performance was estimated using leave-one-out cross-validation.
Validation cohort
The clinical prediction rule was externally validated in a cohort
of inborn singleton newborns with a gestational age #32.0 weeks
admitted to the NICU (level III) of the Ma´xima Medical Centre,
Veldhoven, Netherlands between January 1, 2009 and December
31, 2010. Retrospective data retrieval from maternal and neonatal
medical charts was performed for the variables included in both
clinical prediction rules. Data were anonymised before storage.
Similar to the derivation cohort, placenta sampling and fixation
was standardised and presence of chorioamnionitis and additional
fetal inflammatory response was scored according to international
guidelines [14]. Individual composite scores were calculated for
both prediction rules with positive test scores defined by the
optimum cut-off values identified in the derivation cohort. Again,
relevant test statistics were computed from two-by-two contingen-
cy tables. Analyses were performed using SPSS 16.0 software
(SPSS, Inc, Chicago, IL).
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Results
Clinical prediction rule development
The derivation cohort was composed of all 216 singletons from
a cohort of 301 newborns described previously [2,8,19]. Of these,
84 (39%) had HC, while 51 (24%) had additional signs of fetal
involvement. Placental pathology and relevant clinical data were
available for all mother-newborn pairs. Newborns with HC were
more often born vaginally, were of lower gestational age but had a
higher birth weight and placental weight as compared to those
without HC (Table 1). Accordingly, they were less likely to be
SGA. Their mothers more often experienced PPROM and clinical
chorioamnionitis, and less often had preeclampsia and HELLP
syndrome. The same differences were present between newborns
with HCF and those without, with the exception of birth weight,
which was not significantly different between these groups.
The final logistic regression models for prediction of HC and
HCF are shown in Tables 2 and 3. Clinical prediction rules based
on the weighted beta values were computed, yielding the following
formulas: HC score = 36‘no preeclampsia’+36‘not SGA’+26‘cli-
nical chorioamnionitis’+26‘gestational age #28.0 week-
s’+16‘PPROM’+16‘vaginal delivery’ (maximum score = 12;
Table 2), and HCF score = 26‘no preeclampsia’+16‘P-
PROM’+16‘gestational age #28.0 weeks’+16‘not SGA’+16‘cli-
nical chorioamnionitis’ (maximum score = 6; Table 3). ROC
curves showed high predictive ability for both clinical prediction
rules, with an area under the curve of 0.95 (95% CI 0.92–0.98) for
HC and 0.92 (95% CI 0.88–0.96) for HCF (Figure 1). These
values were very similar to those derived from prediction by the
actual regression model itself (0.95 [95% CI 0.93–0.98], and 0.93
[95% CI 0.89–0.96], respectively), showing no important loss of
information by simplification into a points-based clinical predic-
tion rule. Based on a preference for high sensitivity over specificity,
final cut-off values of $7 and $4 were selected for HC and HCF,
respectively. Using these cut-offs, positive and negative predictive
values of the HC clinical prediction rule were 80% (95% CI 74–
84%) and 93% (95% CI 88–96%), respectively (Figure 1).
Corresponding figures for the HCF clinical prediction rule were
59% (95% CI 52–62%) and 97% (95% CI 93–99%). Internal
cross-validation yielded 87% accuracy for the HC clinical
prediction rule and of 83% for the HCF prediction rule.
Additional test characteristics are shown in Table 4.
External validation
The validation cohort was derived from a birth cohort of 206
inborn singleton newborns. Placental pathology was available for
183 (89%) of these. Distribution of the predictor variables over
both cohorts is shown in Table 5. Newborns with missing placental
pathology were less often delivered by caesarean section (17 vs.
45%, p= 0.01). No other important differences in predictor
variables were present between newborns with and without
available placental pathology. HC was diagnosed in 80 placentas
(44%), and HCF was present in 40 (22%). Validation of the clinical
prediction rules led to an expected small drop in accuracy (73%
for HC and 76% for HCF), affecting PPV (60 [95% CI 54–64]
and 47 [39–53], respectively) rather than NPV (90 [83–95] and 93
[88–97], respectively).
Table 1. Derivation cohort baseline characteristics.
No HC
(n = 132)
HC
(n = 84) P-value
No HCF
(n = 165)
HCF
(n = 51) P-value
Ethnicity 0.38 0.38
Western Europe 92 (70) 57 (68) 118 (72) 31 (61)
Eastern Europe/Asia 3 (2) 5 (6) 6 (4) 2 (4)
Mediterranean 11 (8) 7 (8) 12 (7) 6 (12)
Sub-Saharan Africa 11 (8) 10 (12) 13 (8) 8 (16)
South America/Caribbean 15 (11) 5 (6) 16 (10) 4 (8)
Maternal age (years; mean 6 SD) 30.565.7 30.365.6 0.75 30.465.6 30.465.8 0.95
Gravidity (median (IQR)) 1 (1–3) 2 (1–3) 0.17 1 (1–2) 2 (1–3) 0.09
Parity (median (IQR)) 1 (1–2) 1 (1–2) 0.45 1 (1–2) 1 (1–2) 0.29
Betamethasone (% full course) 92 (70) 65 (77) 0.22 120 (73) 37 (73) 0.98
Preeclampsia (%) 88 (67) 3 (4) ,.001 90 (55) 1 (2) ,.001
HELLP (%) 58 (44) 3 (4) ,.001 61 (37) 0 (0) ,.001
PPROM (%) 11 (8) 49 (58) ,.001 24 (15) 36 (71) ,.001
Clinical chorioamnionitis (%) 10 (8) 52 (62) ,.001 25 (15) 37 (73) ,.001
Mode of delivery (% vaginal) 17 (13) 59 (70) ,.001 40 (24) 36 (71) ,.001
Gestational age (weeks; mean 6 SD) 29.761.6 28.662.1 ,.001 29.661.6 28.262.2 ,.001
Gender (% male) 63 (48) 49 (58) 0.13 86 (52) 26 (51) 0.89
Birth weight (grams; mean 6 SD) 10696329 12406370 ,.001 11266353 11666362 0.50
Small for gestational age (%) 63 (48) 3 (4) ,.001 64 (39) 2 (4) ,.001
Placental weight (g; mean 6 SD) 225675 2976101 ,.001 243693 286687 0.004
Derivation cohort baseline characteristics. for mother-infant pairs with and without histological chorioamnionitis (HC; left), and with and without histological
chorioamnionitis with fetal involvement (HCF; right). Abbreviations: SD= standard deviation; IQR = interquartile range; HELLP = haemolysis, elevated liver enzymes, low
platelets; PPROM=preterm premature rupture of membranes.
doi:10.1371/journal.pone.0046217.t001
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Discussion
In a well-defined cohort of very preterm newborns reported
previously [2,8,19], we developed a clinical prediction rule for
histological chorioamnionitis and for histological chorioamnionitis
with fetal involvement. Using a simple set of clinical variables
generally available in the clinical setting, both HC and HCF could
be predicted at birth with high accuracy, with an expected small
drop in prediction rule performance at external validation. The
prediction rules presented here carry future potential in facilitation
of subgroup-targeted early intervention strategies.
The current study has several strengths. Development and
validation were performed according to accepted standards
[20,21]. A large, prospective cohort with complete data was used
for prediction rule development. Predictors were well defined and
outcome assessment was performed in a blinded fashion according
to widely used published standards [14]. External validation was
performed using a cohort of consecutively inborn singletons with a
high rate of available placental pathology. The temporal and
geographical spacing between the derivation and validation cohort
increase generalisability of the results. Conversely, external
validation is limited somewhat by the retrospective nature of the
validation cohort. Furthermore the higher rate of vaginal deliveries
in newborns without placental pathology indicates a minor
selection bias, the effect of which is likely to be small given the
low weight carried by mode of delivery in the prediction rules. It is
important to note that some diagnostic performance was lost at
external validation, a phenomenon observed almost invariably
during any process of clinical prediction rule development [22].
During further evaluation of the decision rule it must be kept in
mind that it is derived from a cohort of very preterm singleton
newborns, and should therefore not be extrapolated to multiplets
and more mature newborns without further testing. Application of
our model to multiplets in the derivation cohort showed it had no
discriminative value in these newborns (not shown), which is in
agreement with the distinct mechanisms underlying preterm
delivery in this subgroup. Finally, because several diagnostic
criteria for histological chorioamnionitis exist [14,23–26], the
generalisability of our prediction rule for chorioamnionitis
diagnosed by criteria other than those by Redline and co-workers
[14], requires evaluation.
To date, chorioamnionitis remains a troublesome diagnostic
entity. Most cases are clinically silent and there is no reliable way
of determining its presence, let alone severity, in a non-invasive
manner before delivery [27,28]. Results of placental pathology, the
current gold standard for diagnosis, often take days to weeks to
obtain. The prediction rules presented here underline the distinct
clinical characteristics of affected patients as compared to other
preterm newborns. As noted earlier, the primary causes of preterm
birth among singletons – preeclampsia and chorioamnionitis –
rarely co-exist [3,29]. Therefore it is not surprising to see how
factors known to characterise either of these groups – preeclampsia
and SGA on the one hand, clinical chorioamnionitis, PPROM and
vaginal delivery on the other – comprise the major part of the
prediction models. The additional contribution of gestational age
is explained by its known inverse relationship with chorioamni-
onitis incidence: lower gestational age increases the likelihood of
chorioamnionitis [1,3]. The mutual exclusion of many of the
aforementioned variables would potentially favour classification
and regression-tree (CART) analyses rather than points-based
prediction rules as the most distinctive way to identify chorioam-
nionitis-exposed newborns. CART analyses were evaluated
simultaneously in the current study and were disregarded for
their slightly worse test performance (data not shown). Similarly, it
may seem appealing to restrict the analyses to subgroups of
patients particularly at risk of histological chorioamnionitis, such
as those with preterm labour or PPROM. However, PPROM for
example was absent in 42% of newborns in the derivation cohort
and in 47% in the validation cohort. Consequently, restriction of
analyses to PPROM patients would not have allowed identifying
over 80% of patients with histological chorioamnionitis in the
cohort, and thus using a combination of risk factors in a model-
based approach as presented here is favourable.
Few previous studies have evaluated multivariable models for
chorioamnionitis prediction. Using a combination of clinical and
laboratory or ultrasound parameters, others were able to predict
intra-amniotic inflammation and infection, but with test charac-
teristics inferior to those presented here [30–32]. Balaguer and
colleagues showed that an algorithm could improve classification
of the alleged underlying causes of prematurity in a small cohort
[33]. However, it is unclear whether placental histology or other
tests were performed to confirm chorioamnionitis. Several
biological markers have previously been evaluated as a diagnostic
tool to identify the presence and severity of chorioamnionitis
shortly after birth. The marker most extensively investigated in this
regard is probably interleukin-6 (IL-6), predominantly measured in
cord blood. Its sensitivity and specificity for diagnosing HC range
Table 2. Logistic regression model and clinical prediction rule
for histological chorioamnionitis.
Factor Beta SE P-value
Prediction rule
(points per item)
No preeclampsia 2.72 0.74 ,.001 3
Not SGA 2.50 0.84 .003 3
Clinical chorioamnionitis 1.64 0.55 .003 2
Gestational age #28.0 wks1.34 0.61 .028 2
PPROM 1.02 0.52 .048 1
Vaginal delivery 0.87 0.51 .086 1
Intercept 26.89 1.12 ,.001 Total = 12
Logistic regression model and clinical prediction rule for prediction of
histological chorioamnionitis. Abbreviations: SE = standard error; SGA = small for
gestational age; PPROM=preterm premature rupture of membranes.
doi:10.1371/journal.pone.0046217.t002
Table 3. Logistic regression model and clinical prediction rule
for histological chorioamnionitis with fetal involvement.
Factor Beta SE P-value
Prediction rule
(points per
item)
No preeclampsia 2.26 1.10 .039 2
PPROM 1.72 0.49 ,.001 1
Gestational age #27.0 wks 1.70 0.59 .004 1
Not SGA 1.60 0.91 .077 1
Clinical chorioamnionitis 1.30 0.47 .006 1
Intercept 26.07 1.28 ,.001 Total = 6
Logistic regression models and clinical prediction rules for prediction of
histologic chorioamnionitis with fetal involvement. Abbreviations: SE = standard
error; PPROM=preterm premature rupture of membranes; SGA= small for
gestational age.
doi:10.1371/journal.pone.0046217.t003
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from 73% to 74%, and 77% to 85%, respectively [15,34,35].
Diagnostic properties reported for HCF are within the same range
[16,17,34,35]. Several other molecular and haematologic markers
have been evaluated, but to date none has shown to carry
sufficient predictive ability to justify routine clinical use
[17,34,36,37]. Recent studies showed that test accuracy can be
enhanced by combining several molecular markers in amniotic or
cervical fluid [38,39]. However, external validation was not
performed, and obvious drawbacks remain the need for an
invasive procedure (for amniotic fluid), as well as costs and time
required for proteomic profiling.
To the best of our knowledge, the diagnostic properties of the
models presented here are at least equivalent to those of any non-
invasive biological marker reported to date, most of which have
not been externally validated. Moreover, the prediction rules are
easy to use, cheap, and their results are readily available. The
models may be used to identify at birth newborns exposed to
various degrees of antenatal inflammation. As such, they can
facilitate the development of decision rules in future studies to
optimise and individualise treatment of preterm newborns. In
addition they may be used for predefined subgroup analyses in
clinical trials to investigate their value in predicting differential
therapeutic responses. Negative predictive value were particularly
well preserved during external validation of the prediction rules
presented here, making these predominantly useful to guide
targeted therapies with large subgroup-associated benefits and
little adverse effects at the population level. Whereas in the current
study we have preferred high sensitivity to specificity the model
obviously allows for tailored selection of a less conservative cut-off
value to increase specificity over sensitivity.
Evidence from observational studies suggests that infants
exposed to varying degrees of antenatal inflammation may
particularly benefit from increased surfactant dosing [8,10] and
restrictive use of invasive ventilation [8,11–13]. Furthermore, a
randomised controlled trial identified subgroup-associated benefits
of postnatal corticosteroids in infants with chorioamnionitis [9].
Results of placental pathology are generally unavailable when
decisions regarding the initiation of such interventions are
required. Future studies should evaluate the potential value of
the use of the clinical prediction rules presented here to guide such
decision-making. Another potential field of interest is antibiotic
prophylaxis for prevention of early onset sepsis in preterm
newborns. Its use is widespread, although serious potential side-
effects are well recognised [40–42]. Individualised antibiotic
prophylaxis based on prediction of sepsis risk may well improve
outcome at the group level by reducing unnecessary and
potentially harmful use of antibiotics. The clinical prediction rules
presented here could guide such individualisation of therapy.
Conclusion
Development of prediction strategies to identify subgroups of
preterm newborns that may benefit from a targeted therapeutic
approach is essential to improve future outcomes in neonatology.
Presented here is the development and external validation of a
multivariable diagnostic prediction rule for histological chorioam-
nionitis and histological chorioamnionitis with fetal involvement at
Figure 1. ROC curve and PPV-NPV plot of clinical prediction rule for histological chorioamnionitis (A+B) and histological
chorioamnionitis with fetal involvement (C+D). Figures in PPV-NPV plots indicate inclusive ($) cut-off values for positive test scores.
doi:10.1371/journal.pone.0046217.g001
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birth in preterm newborns. The models are composed of small sets
of clinical variables readily available in everyday practice and are
therefore broadly applicable and simple to use. The models’
diagnostic properties are encouraging and appeal for further
evaluation to assess their value in supporting clinical decision-
making.
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Table 4. Clinical prediction rule test characteristics.
HC prediction rule HCF prediction rule
Derivation cohort Validation cohort Derivation cohort Validation cohort
Characteristic Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
Area under ROC curve 0.95 (0.92–0.98) 0.81 (0.74–0.87) 0.92 (0.88–0.96) 0.83 (0.77–0.89)
Positive test score $7 $4
Sensitivity 0.89 (0.82–0.94) 0.89 (0.80–0.94) 0.92 (0.82–0.97) 0.80 (0.66–0.90)
Specificity 0.86 (0.81–0.89) 0.64 (0.58–0.67) 0.80 (0.77–0.82) 0.75 (0.71–0.78)
Accuracy (%) 87 (82–91) 73 (67–78) 83 (78–85) 76 (70–80)
PPV (%) 80 (74–84) 60 (54–64) 59 (52–62) 47 (39–53)
NPV (%) 93 (88–96) 90 (83–95) 97 (93–99) 93 (88–97)
LLR+ 6.20 (4.36–8.36) 2.44 (1.92–2.88) 4.61 (3.52–5.30) 3.18 (2.26–4.02)
LLR2 0.13 (0.07–0.22) 0.18 (0.08–0.34) 0.10 (0.03–0.24) 0.27 (0.13–0.48)
Diagnostic Odds Ratio 49.6 (19.9–127.6) 13.6 (5.6–34.3) 47.0 (14.8–166.2) 11.9 (4.7–31.0)
Clinical prediction rule test characteristics for histological chorioamnionitis (HC) and histological chorioamnionitis with fetal involvement (HCF). Abbreviations:
ROC= receiver operating characteristics; PPV= positive predictive value; NPV= negative predictive value; LLR+= likelihood ratio of positive test; LLR2= likelihood ratio
of negative test.
doi:10.1371/journal.pone.0046217.t004
Table 5. Distribution of predictor variables among different subsets within the derivation and validation cohorts.
Derivation cohort
(n = 216)
Validation cohort
(n = 206)
No HC
(n = 132)
HC
(n = 84)
No HCF
(n = 165)
HCF
(n = 51)
Placental pathology
unavailable
(n = 23)
Placental
pathology
available
(n = 183)
Placental pathology available
(n = 183)
No HC
(n = 103)
HC
(n = 80)
No HCF
(n = 143)
HCF
(n = 40)
No preeclampsia (%) 44 (33) 81 (96) 75 (46) 50 (98) 19 (83) 135 (74) 60 (58) 75 (94) 95 (66) 40 (100)
Not SGA (%) 69 (52) 81 (96) 101 (61) 49 (96) 22 (96) 162 (89) 83 (81) 78 (98) 122 (85) 40 (100)
Clinical
chorioamnionitis (%)
10 (8) 52 (62) 25 (15) 37 (73) 0 (0) 13 (7) 0 (0) 13 (16) 4 (3) 9 (23)
Gestational age
#27.0 wks (%)
16 (10) 20 (39) 3 (13) 24 (13) 16 (11) 8 (20)
Gestational age
#28.0 wks (%)
26 (20) 33 (39) 3 (13) 41 (22) 19 (18) 22 (28)
PPROM (%) 11 (8) 49 (58) 24 (15) 36 (71) 10 (44) 62 (34) 20 (19) 42 (53) 33 (23) 29 (73)
Vaginal delivery (%) 17 (13) 59 (70) 40 (24) 36 (71) 19 (83) 101 (55) 37 (36) 64 (80) 67 (47) 34 (85)
Abbreviations: HC= histological chorioamnionitis; HCF = histological chorioamnionitis with fetal involvement.
doi:10.1371/journal.pone.0046217.t005
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